Pdt Partners, LLC Immunovant, Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $1,374 - $1,774	90 Added 0.77%	11,779 $182,000
Q4 2022 Feb 14, 2023	SELL	$6.59 - $17.75 $3,334 - $8,981	-506 Reduced 4.15%	11,689 $207,000
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $483,519 - $783,720	-123,033 Reduced 90.98%	12,195 $68,000
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $132,015 - $228,809	26,090 Added 23.91%	135,228 $745,000
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $799,981 - $1.02 Million	109,138 New	109,138 $930,000
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $951,257 - $1.54 Million	-135,700 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $1.28 Million - $2.29 Million	135,700 New	135,700 $1.43 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.